Biocytogen: One-stop Solution from Target to IND Application
Biocytogen provides one-stop solution for next-generation drug development, from target to IND application to the global biomedical communities. Empowered by its cutting-edge gene editing technologies and state-of-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery. The technical teams in Bicytogen support a comprehensive portfolio of products and services, covering in vivo/in vitro preclinical services, animal model generation, fully human antibody (via RenMab™ Mouse), therapeutic antibody discovery and development services, CMC/CDMO, and regulatory affairs support. Biocytogen collaborates with more than 70% of top 50 pharmaceutical and numerous biotech start-up companies worldwide. Together, we discover innovative medicines for a better, healthier world.
- Advance life sciences with high-quality and customized models to push the boundary of utilization of humanized target models in biomedical research
- Develops technological platforms to significantly shorten the next-generation drug discovery and development process
- Empower scientists in drug discovery by providing the necessary expertise to unstuck bottlenecks in research
- Be a global leader in all-round preclinical services with unique value propositions to the clients